Lactobacilli and Bifidobacterium as anti-atherosclerotic agents

被引:2
|
作者
Abdi, Milad [1 ]
Ghaleh, Hadi Esmaeili Gouvarchin [2 ]
Ranjbar, Reza [3 ]
机构
[1] Kerman Univ Med Sci, Res Ctr Trop & Infect Dis, Kerman, Iran
[2] Baqiyatallah Univ Med Sci, Appl Virol Res Ctr, Tehran, Iran
[3] Baqiyatallah Univ Med Sci, Syst Biol & Poisonings Inst, Mol Biol Res Ctr, Tehran, Iran
关键词
Atherosclerosis; Bifidobacterium; Hypercholesterolemia; Inflammation; Lactobacilli; Oxidative stress; TMAO; TRIMETHYLAMINE N-OXIDE; BILE-SALT HYDROLASE; CHAIN FATTY-ACIDS; LIVER-X-RECEPTOR; CHOLESTEROL-LOWERING EFFICACY; PICK C1-LIKE 1; LIPID PROFILE; OXIDATIVE STRESS; SERUM-CHOLESTEROL; RISK-FACTORS;
D O I
10.22038/IJBMS.2022.63860.14073
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Atherosclerosis is the thickening or hardening of the arteries which is caused by a buildup of atheromatous plaque in the inner lining of an artery. Hypercholesterolemia, inflammation, oxidative stress, and trimethylamine N-oxide (TMAO) are important risk factors for atherosclerosis. Therefore, this study aimed to review the anti-atherosclerotic effects of Lactobacilli and Bifidobacterium via improving lipid profile and reducing the effects of oxidative stress, inflammation, and TMAO. To prepare the present review, several databases such as Scopus, PubMed, and Google Scholar were searched, and relevant articles from 1990 until 2022 were selected and reviewed. The present review showed that Lactobacilli and Bifidobacterium reduce the risk of atherosclerosis in both in vitro and in vivo studies by breaking down or altering cholesterol metabolism with the help of their by-products and by reducing inflammation and oxidative stress and TMAO. Consumption of Lactobacilli and Bifidobacterium can be useful in prevention of atherosclerosis.
引用
收藏
页码:934 / 946
页数:13
相关论文
共 50 条
  • [21] ARTIFICIAL HDL AS AN ANTI-ATHEROSCLEROTIC DRUG
    OREKHOV, AN
    MISHARIN, AY
    TERTOV, VV
    KHASHIMOV, KA
    POKROVSKY, SN
    REPIN, VS
    SMIRNOV, VN
    LANCET, 1984, 2 (8412): : 1149 - 1150
  • [22] ASTAXANTHIN: AN ANTI-ATHEROSCLEROTIC TREATMENT IN MICE
    Anto-Michel, N.
    Maechler, H.
    Zirlik, A.
    ATHEROSCLEROSIS, 2023, 379
  • [23] CETABEN SODIUM, AN ANTI-ATHEROSCLEROTIC AGENT
    ALBRIGHT, JD
    SCHAFFER, SA
    SHEPHERD, RG
    JOURNAL OF PHARMACEUTICAL SCIENCES, 1979, 68 (07) : 936 - 937
  • [24] Identification and Kinetic Characterization of Novel Inhibitors of Human Cholesterol Esterase as Anti-Atherosclerotic Agents
    Sheikh, M.
    Steinkrueger, M.
    Augner, D.
    Guetschow, M.
    Herzig, S.
    Schmalz, H-G
    Pietsch, M.
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2013, 386 : S78 - S78
  • [25] Insulin Is an Anti-inflammatory and Anti-atherosclerotic Hormone
    Dandona, Paresh
    Aljada, Ahmad
    O'Donnell, Amy
    Dhindsa, Sandeep
    Garg, Rajesh
    METABOLIC SYNDROME AND RELATED DISORDERS, 2004, 2 (02) : 137 - +
  • [26] Mechanisms Underlying the Anti-Atherosclerotic Effects of EGCG
    Wang, Lili
    Pan, Qun
    Tang, Chunlian
    CURRENT MOLECULAR MEDICINE, 2025,
  • [27] Animal models to evaluate anti-atherosclerotic drugs
    Priyadharsini, Raman P.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2015, 29 (04) : 329 - 340
  • [28] Hydrochlorothiazide abolishes the anti-atherosclerotic effect of quinapril
    Fonseca, FAH
    Ihara, SSM
    Izar, MCO
    Silva, EP
    Kasinski, N
    Lopes, IEL
    Pinto, LESA
    Paiva, TB
    Tufik, S
    de Paola, AAV
    Carvalho, ACC
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2003, 30 (10) : 779 - 785
  • [29] Anti-atherosclerotic effects of the hexapeptide angiotensin IV
    Vinh, Antony
    Widdop, Robert
    Gaspari, Tracey
    FASEB JOURNAL, 2008, 22
  • [30] Laboratory surrogates for anti-atherosclerotic drug development
    Stein, E
    AMERICAN JOURNAL OF CARDIOLOGY, 2001, 87 (4A): : 21A - 26A